Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

Next Previous
Trial Profile

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SenL-T7 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Hebei Senlang Biotechnology

Most Recent Events

  • 01 Dec 2023 Results (n=60 from studies NCT04572308 and NCT04916860) assessing safety and efficacy of patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy published in the American Journal of Hematology
  • 15 Jun 2023 Results (n=10 from NCT04572308 &NCT04916860) assessing the efficacy and safety of NS7CAR T-cells for relapsed or refractory (R/R) T-ALL/LBL with CNSinvolvement in phase I/II clinical trial presented at the 28th Congress of the European Haematology Association
  • 13 Dec 2022 Results (n=53 from two studies NCT04572308 &NCT04916860) assessing the effect of CAR-T Cell Therapy in Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top